Preventive drug therapy and contralateral breast cancer: summary of the evidence of clinical trials and observational studies

References

• Curtis RE, Ron E, Hankey BF, et al. New malignancies following breast cancer. In: Curtis RE, Freedman M, Ron E, et al., editors. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. Bethesda (MD): National Institutes of Health (NIH); 2006. p. 181–205.
   Google Scholar
• Evans HS, Lewis CM, Robinson D, et al. Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. Br J Cancer. 2001;84:435–440.
   PubMed Web of Science ®Google Scholar
• Spronk I, Schellevis FG, Burgers JS, et al. Incidence of isolated local breast cancer recurrence and contralateral breast cancer: a systematic review. The Breast. 2018;39:70–79.
   PubMed Web of Science ®Google Scholar
• Narod SA. Bilateral breast cancers. Nat Rev Clin Oncol. 2014;11:157–166.
   PubMed Web of Science ®Google Scholar
• Yao K, Sisco M, Bedrosian I. Contralateral prophylactic mastectomy: current perspectives. Int J Women's Health. 2016;8:213–223.
   PubMed Web of Science ®Google Scholar
• Fayanju OM, Stoll CR, Fowler S, et al. Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg. 2014;260:1000–1010.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group, Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–784.
   PubMed Web of Science ®Google Scholar
• Cuzick J. Preventive therapy for cancer. Lancet Oncol. 2017;18:e472–e482.
   PubMed Web of Science ®Google Scholar
• Davies KR, Cantor SB, Brewster AM. Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy. Int J Women's Health. 2015;7:181–187.
   PubMed Web of Science ®Google Scholar
• Jordan VC. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer. 2007;7:46–53.
   PubMed Web of Science ®Google Scholar
• Gnant M, Harbeck N, Thomssen C. St. Gallen 2011: summary of the consensus discussion. Breast Care (Basel). 2011;6:136–141.
   PubMed Web of Science ®Google Scholar
• Cuzick J. Progress in preventive therapy for cancer: a reminiscence and personal viewpoint. Br J Cancer. 2018;118:1155–1161.
   PubMed Web of Science ®Google Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–816.
   PubMed Web of Science ®Google Scholar
• Bertelsen L, Bernstein L, Olsen JH, et al. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst. 2008;100:32–40.
   PubMedGoogle Scholar
• Cook LS, Weiss NS, Schwartz SM, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst. 1995;87:1359–1364.
   PubMedGoogle Scholar
• Langballe R, Mellemkjaer L, Malone KE, et al. Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study. Breast Cancer Res. 2016;18:65.
   PubMed Web of Science ®Google Scholar
• Mellemkjaer L, Steding-Jessen M, Frederiksen K, et al. Risk of contralateral breast cancer after tamoxifen use among Danish women. Ann Epidemiol. 2014;24:843–848.
   PubMed Web of Science ®Google Scholar
• Newcomb PA, Solomon C, White E. Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat. 1999;53:271–277.
   PubMed Web of Science ®Google Scholar
• Schaapveld M, Visser O, Louwman WJ, et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat. 2008;110:189–197.
   PubMed Web of Science ®Google Scholar
• Vichapat V, Garmo H, Holmqvist M, et al. Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study. J Clin Oncol. 2012;30:3478–3485.
   PubMed Web of Science ®Google Scholar
• Bouchardy C, Benhamou S, Fioretta G, et al. Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat. 2011;127:233–241.
   PubMed Web of Science ®Google Scholar
• Li CI, Daling JR, Porter PL, et al. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer. Cancer Res. 2009;69:6865–6870.
   PubMed Web of Science ®Google Scholar
• Li CI, Malone KE, Weiss NS, et al. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst. 2001;93:1008–1013.
   PubMedGoogle Scholar
• Gierach GL, Curtis RE, Pfeiffer RM, et al. Association of adjuvant tamoxifen and aromatase inhibitor therapy with contralateral breast cancer risk among us women with breast cancer in a general community setting. JAMA Oncol. 2017;3:186–193.
   PubMed Web of Science ®Google Scholar
• Kramer I, Schaapveld M, Oldenburg HSA, et al. The influence of adjuvant systemic regimens on contralateral breast cancer risk and receptor subtype. J Natl Cancer Inst. 2019;111:709–718.
   PubMedGoogle Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–1467.
   PubMed Web of Science ®Google Scholar
• Hackshaw A, Roughton M, Forsyth S, et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol. 2011;29:1657–1663.
   PubMed Web of Science ®Google Scholar
• Rosell J, Nordenskjold B, Bengtsson NO, et al. Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen. Acta Oncol. 2017;56:614–617.
   PubMed Web of Science ®Google Scholar
• Gizzo S, Saccardi C, Patrelli TS, et al. Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications. Obstetrical Gynecol Surv. 2013;68:467–481.
   PubMed Web of Science ®Google Scholar
• Waters EA, McNeel TS, Stevens WM, et al. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat. 2012;134:875–880.
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Philadelphia, Pa). 2010;3:696–706.
   PubMed Web of Science ®Google Scholar
• Schneider R, Barakat A, Pippen J, et al. Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update. Breast Cancer Targets Ther. 2011;3:113–125.
   PubMedGoogle Scholar
• Early Breast Cancer Trialists' Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341–1352.
   PubMed Web of Science ®Google Scholar
• Jensen MB, Laenkholm AV, Offersen BV, et al. The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007-2016. Acta Oncol. 2018;57:13–18.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 – a randomized controlled phase III trial. J Clin Oncol. 2013;31:1398–1404.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375:209–219
   PubMed Web of Science ®Google Scholar
• Morden JP, Alvarez I, Bertelli G, et al. Long-term follow-up of the Intergroup Exemestane Study. J Clin Oncol. 2017;35:2507–2514.
   PubMed Web of Science ®Google Scholar
• Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol. 2017;18:1502–1511.
   PubMed Web of Science ®Google Scholar
• Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL Trial (BOOG 2006-05). J Natl Cancer Inst. 2018;110:40–48.
   Google Scholar
• Colleoni M, Luo W, Karlsson P, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19:127–138.
   PubMed Web of Science ®Google Scholar
• Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379:122–137
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37:423–438.
   PubMed Web of Science ®Google Scholar
• Carlson RW, Theriault R, Schurman CM, et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor–positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol. 2010;28:3917–3921.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–2391.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383:1041–1048.
   PubMed Web of Science ®Google Scholar
• Black DM, Rosen CJ. Postmenopausal osteoporosis. N Engl J Med. 2016;374:254–262.
   PubMed Web of Science ®Google Scholar
• Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014;15:997–1006.
   PubMed Web of Science ®Google Scholar
• Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29:1221–1227.
   PubMed Web of Science ®Google Scholar
• Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24:398–405.
   PubMed Web of Science ®Google Scholar
• Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584–593.
   PubMed Web of Science ®Google Scholar
• Hadji P, Coleman RE, Wilson C, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol. 2016;27:379–390.
   PubMed Web of Science ®Google Scholar
• Danish Breast Cancer Cooperative Group. Medicinsk behandling; 2016 [cited 2019 Jul 17]. Available from: http://www.dbcg.dk/
   Google Scholar
• Morgan G, Lipton A. Antitumor effects and anticancer applications of bisphosphonates. Semin Oncol. 2010;37:S30–S40.
   PubMed Web of Science ®Google Scholar
• Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res. 2010;12:214
   PubMed Web of Science ®Google Scholar
• Ou YJ, Chiu HF, Wong YH, et al. Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2017;26:1286–1295.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353–1361.
   PubMed Web of Science ®Google Scholar
• Monsees GM, Malone KE, Tang M-T, et al. Bisphosphonate use after estrogen receptor–positive breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst. 2011;103:1752–1760.
   PubMedGoogle Scholar
• Kwan ML, Shi JM, Habel LA, et al. Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen. Breast Cancer Res Treat. 2016;156:379–389.
   PubMed Web of Science ®Google Scholar
• Ahern TP, Pedersen L, Tarp M, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011;103:1461–1468
   PubMed Web of Science ®Google Scholar
• Boudreau DM, Yu O, Chubak J, et al. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat. 2014;144:405–416.
   PubMed Web of Science ®Google Scholar
• Langballe R, Cronin-Fenton D, Dehlendorff C, et al. Statin use and risk of contralateral breast cancer: a nationwide cohort study. Br J Cancer. 2018;119:1297–1305.
   PubMed Web of Science ®Google Scholar
• Oppong BA, Pharmer LA, Oskar S, et al. The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Med. 2014;3:1025–1034.
   PubMed Web of Science ®Google Scholar
• Calip GS, Yu O, Hoskins KF, et al. Associations between diabetes medication use and risk of second breast cancer events and mortality. Cancer Causes Control. 2015;26:1065–1077.
   PubMed Web of Science ®Google Scholar
• Bens A, Friis S, Dehlendorff C, et al. Low-dose aspirin use and risk of contralateral breast cancer: a Danish nationwide cohort study. Prev Med. 2018;116:186–193
   PubMed Web of Science ®Google Scholar
• Bens A, Cronin-Fenton D, Dehlendorff C, et al. Non-aspirin NSAIDs and contralateral breast cancer risk. Int J Cancer. 2018;144:1243–1250.
   PubMed Web of Science ®Google Scholar
• Chen L, Malone KE, Li CI. Use of antihypertensive medications not associated with risk of contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2015;24:1423–1426.
   PubMed Web of Science ®Google Scholar
• Veronesi U, Mariani L, Decensi A, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol. 2006;17:1065–1071
   PubMed Web of Science ®Google Scholar
• Chou R, Dana T, Blazina I, et al. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016;316:2008–2024.
   PubMed Web of Science ®Google Scholar
• Ahern TP, Lash TL, Damkier P, et al. Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol. 2014;15:e461–8.
   PubMed Web of Science ®Google Scholar
• Campbell MJ, Esserman LJ, Zhou Y, et al. Breast cancer growth prevention by statins. Cancer Res. 2006;66:8707–8714.
   PubMed Web of Science ®Google Scholar
• Borgquist S, Bjarnadottir O, Kimbung S, et al. Statins – a role in breast cancer therapy?. J Intern Med. 2018;284:346–357.
   PubMed Web of Science ®Google Scholar
• Vinayak S, Kurian AW. Statins may reduce breast cancer risk, particularly hormone receptor-negative disease. Curr Breast Cancer Rep. 2009;1:148–156.
   PubMedGoogle Scholar
• Bonovas S, Filioussi K, Tsavaris N, et al. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005;23:8606–8612.
   PubMed Web of Science ®Google Scholar
• Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat. 2012;135:261–269.
   PubMed Web of Science ®Google Scholar
• Wu QJ, Tu C, Li YY, et al. Statin use and breast cancer survival and risk: a systematic review and meta-analysis. Oncotarget. 2015;6:42988–43004.
   PubMedGoogle Scholar
• Islam MM, Yang HC, Nguyen PA, et al. Exploring association between statin use and breast cancer risk: an updated meta-analysis. Arch Gynecol Obstet. 2017;296:1043–1053
   PubMed Web of Science ®Google Scholar
• Borgquist S, Tamimi RM, Chen WY, et al. Statin use and breast cancer risk in the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev. 2016;25:201–206.
   PubMed Web of Science ®Google Scholar
• Woditschka S, Habel LA, Udaltsova N, et al. Lipophilic statin use and risk of breast cancer subtypes. Cancer Epidemiol Biomarkers Prev. 2010;19:2479–2487.
   PubMed Web of Science ®Google Scholar
• Leone A, Di Gennaro E, Bruzzese F, et al. New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat Res. 2014;159:355–376.
   PubMedGoogle Scholar
• Thompson AM. Molecular pathways: preclinical models and clinical trials with metformin in breast cancer. Clin Cancer Res. 2014;20:2508–2515.
   PubMed Web of Science ®Google Scholar
• Chappell J, Leitner JW, Solomon S, et al. Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence. J Biol Chem. 2001;276:38023–38028.
   PubMed Web of Science ®Google Scholar
• Col NF, Ochs L, Springmann V, et al. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat. 2012;135:639–646.
   PubMed Web of Science ®Google Scholar
• Zhang P, Li H, Tan X, et al. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 2013;37:207–218.
   PubMed Web of Science ®Google Scholar
• Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;11:81s–110s
   PubMed Web of Science ®Google Scholar
• Maity G, De A, Das A, et al. Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition. Lab Invest. 2015;95:702–717.
   PubMed Web of Science ®Google Scholar
• Dai ZJ, Ma XB, Kang HF, et al. Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in vitro and in vivo. Cancer Cell Int. 2012;12:53.
   PubMed Web of Science ®Google Scholar
• de Pedro M, Baeza S, Escudero MT, et al. Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2015;149:525–536.
   PubMed Web of Science ®Google Scholar
• Lu L, Shi L, Zeng J, et al. Aspirin as a potential modality for the chemoprevention of breast cancer: a dose-response meta-analysis of cohort studies from 857,831 participants. Oncotarget 2017;8:40389–40401.
   PubMedGoogle Scholar
• Pasquier E, Ciccolini J, Carre M, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011;2:797–809.
   PubMed Web of Science ®Google Scholar
• Napoleone E, Cutrone A, Cugino D, et al. Inhibition of the renin-angiotensin system downregulates tissue factor and vascular endothelial growth factor in human breast carcinoma cells. Thrombosis Res. 2012;129:736–742.
   PubMed Web of Science ®Google Scholar
• Du N, Feng J, Hu LJ, et al. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling. Oncol Rep. 2012;27:1893–1903.
   PubMed Web of Science ®Google Scholar
• Ni H, Rui Q, Zhu X, et al. Antihypertensive drug use and breast cancer risk: a meta-analysis of observational studies. Oncotarget. 2017;8:62545–62560.
   PubMedGoogle Scholar
• Garattini E, Bolis M, Garattini SK, et al. Retinoids and breast cancer: from basic studies to the clinic and back again. Cancer Treatment Rev. 2014;40:739–749.
   PubMed Web of Science ®Google Scholar
• Nichols HB, Berrington de Gonzalez A, Lacey JV, Jr, et al. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011;29:1564–1569.
   PubMed Web of Science ®Google Scholar
• Manthravadi S, Shrestha A, Madhusudhana S. Impact of statin use on cancer recurrence and mortality in breast cancer: a systematic review and meta-analysis. Int J Cancer. 2016;139:1281–1288.
   PubMed Web of Science ®Google Scholar
• Borgquist S, Giobbie-Hurder A, Ahern TP, et al. Cholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1-98 Study. J Clin Oncol. 2017;35:1179–1188.
   Web of Science ®Google Scholar
• Murphy CC, Bartholomew LK, Carpentier MY, et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134:459–478.
   PubMed Web of Science ®Google Scholar
• Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res. 2008;14:6336–6342.
   PubMed Web of Science ®Google Scholar
• Svensson E, Nielsen RB, Hasvold P, et al. Statin prescription patterns, adherence, and attainment of cholesterol treatment goals in routine clinical care: a Danish population-based study. Clin Epidemiol. 2015;7:213–223.
   PubMed Web of Science ®Google Scholar
• Perreault S, Blais L, Lamarre D, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol. 2005;59:564–573.
   PubMed Web of Science ®Google Scholar
• Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15:291.
   PubMed Web of Science ®Google Scholar
• Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390:1048–1060.
   PubMed Web of Science ®Google Scholar
• Chowdhury M, Euhus D, Onega T, et al. A model for individualized risk prediction of contralateral breast cancer. Breast Cancer Res Treat. 2017;161:153–160.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet. 1985;2:282.
   PubMed Web of Science ®Google Scholar